Incidence And Resolution Of Eribulin-Induced Peripheral Neuropathy (Irene) In Patients With Locally Advanced Or Metastatic Breast Cancer
ANNALS OF ONCOLOGY(2021)
摘要
Eribulin (ERI), a halichondrin-class microtubule dynamics inhibitor, is a typical chemotherapeutic regimen for patients (pts) with previously treated locally advanced or metastatic breast cancer (MBC). Results of pivotal trials showed that about one-third of pts with locally advanced or MBC treated with ERI develop peripheral neuropathy (PN), a common risk with BC chemotherapies. This postauthorization safety study assessed the incidence and severity of ERI-induced PN (EIPN) in pts with locally advanced or MBC.
更多查看译文
关键词
breast cancer,eribulin-induced
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要